⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15042356 | 1.00 | — | — | |
| SCHEMBL3726548 | 1.00 | — | — | |
| SCHEMBL1838790 | 0.83 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL11870833 | 0.82 | HTT (0.41) | — | |
| SCHEMBL15829094 | 0.78 | HTT (0.42) | — | |
| SCHEMBL27663295 | 0.78 | HTT (0.38) | — | |
| SCHEMBL11224853 | 0.77 | CASR (0.36) | — | |
| SCHEMBL16172597 | 0.76 | — | — | |
| SCHEMBL16172598 | 0.76 | — | — | |
| SCHEMBL1487123 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2022173756-A1 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |